CVSI (CV Sciences) FCF Yield %: -6.07 (As of Jun. 26, 2026)


What is CV Sciences FCF Yield %?

CV Sciences CVSI +9.09% FCF Yield % is -6.07 as of Jun. 26, 2026. The stock has 2 warning signs investors should review. Among 1,005 Drug Manufacturers companies, CV Sciences ranks worse than 76.72% on this metric.

FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

As of today, CV Sciences's Trailing 12-Month Free Cash Flow is $-0.30 Mil, and Market Cap is $4.90 Mil. Therefore, CV Sciences's FCF Yield % for today is -6.07%.

The historical rank and industry rank for CV Sciences's FCF Yield % or its related term are showing as below:

CVSI' s FCF Yield % Range Over the Past 10 Years
Min: -132.13   Med: -7.46   Max: 55.56
Current: -6.07


During the past 13 years, the highest FCF Yield % of CV Sciences was 55.56%. The lowest was -132.13%. And the median was -7.46%.

CVSI's FCF Yield % is ranked worse than
76.72% of 1005 companies
in the Drug Manufacturers industry
Industry Median: 0.67 vs CVSI: -6.07

CV Sciences's FCF Margin % for the quarter that ended in Mar. 2026 was 3.07%.


CV Sciences FCF Yield % Explanation

Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.


CV Sciences FCF Yield % Related Terms


CV Sciences FCF Yield % Historical Data

* Premium members only.

The historical data trend for CV Sciences's FCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CV Sciences FCF Yield % Chart

CV Sciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
FCF Yield %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -57.34 -38.25 39.42 -14.11 -4.56

CV Sciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
FCF Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -8.11 13.96 -13.96 -12.83 6.23

CVSI vs INM, GELS, LVRLF: FCF Yield % Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, CV Sciences's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CV Sciences FCF Yield % vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, CV Sciences's FCF Yield % distribution charts can be found below:

* The bar in red indicates where CV Sciences's FCF Yield % falls into.



CV Sciences FCF Yield % Calculation

FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

CV Sciences's FCF Yield % for the fiscal year that ended in Dec. 2025 is calculated as

FCF Yield %=Free Cash Flow / Market Cap
=-0.516 / 11.3138096
=-4.56%

CV Sciences's annualized FCF Yield % for the quarter that ended in Mar. 2026 is calculated as

FCF Yield %=Free Cash Flow * Annualized Factor / Market Cap
=0.098 * 4 / 6.287385
=6.23%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about FCF Yield % →
What does a FCF Yield % of -6.07 mean?
CV Sciences (CVSI) has a FCF Yield % of -6.07 as of Jun. 26, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on CV Sciences and its competitors. According to the industry distribution chart, CV Sciences ranks #771 out of 1005 companies in the Drug Manufacturers industry, placing it in the top 76.7%.
Is CV Sciences' FCF Yield % too high?
CV Sciences' current FCF Yield % is -6.07. Based on the distribution chart, CV Sciences ranks #771 out of 1005 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers.
How does CV Sciences' FCF Yield % compare to INM and GELS?
According to the Drug Manufacturers industry distribution chart, CV Sciences ranks #771 out of 1005 companies for FCF Yield %. This places CV Sciences in the lower half of its industry. The industry median FCF Yield % is 0.67. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Drug Manufacturers company?
The median FCF Yield % among Drug Manufacturers companies is 0.67, based on 1,005 companies in the industry. Companies in the top quartile (top 25%) have a FCF Yield % significantly above this median, while those in the bottom quartile fall well below. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on CV Sciences and its competitors. For the Drug Manufacturers industry, the median FCF Yield % is 0.67 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CV Sciences's current FCF Yield % is -6.07. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CV Sciences stock overvalued right now?
Based on GuruFocus' analysis, CV Sciences (CVSI) is currently considered Modestly Undervalued. The stock's GF Value™ is $0.03, compared to a current price of $0.02 — trading 20% below its estimated fair value. The current FCF Yield % is -6.07. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For CV Sciences (CVSI), the current FCF Yield % is -6.07 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

CV Sciences Business Description

Address 9530 Padgett Street, Suite 107, San Diego, CA, USA, 92126
CV Sciences Inc is a consumer wellness company specializing in nutraceuticals and plant-based foods products. It develops, manufactures, markets, and sells herbal supplements and hemp-based cannabidiol. The company sells its products under tradenames, such as +PlusCBD, PlusCBD Pet, PlusHLTH, Cultured Foods, and Lunar Fox. The company's products are sold in a variety of market sectors, including nutraceutical, beauty care, and specialty foods. The company has one operating segment, which is the business of hemp-based CBD wellness products. Geographically, all of the company's revenue is generated from United States. The company also operates a drug development program focused on developing and commercializing CBD-based novel therapeutics.